BR112022009192A2 - Composição, método para tratar uma doença ocular ou distúrbio ocular, e, uso de um composto - Google Patents

Composição, método para tratar uma doença ocular ou distúrbio ocular, e, uso de um composto

Info

Publication number
BR112022009192A2
BR112022009192A2 BR112022009192A BR112022009192A BR112022009192A2 BR 112022009192 A2 BR112022009192 A2 BR 112022009192A2 BR 112022009192 A BR112022009192 A BR 112022009192A BR 112022009192 A BR112022009192 A BR 112022009192A BR 112022009192 A2 BR112022009192 A2 BR 112022009192A2
Authority
BR
Brazil
Prior art keywords
eye
neovascularization
compound
composition
disease
Prior art date
Application number
BR112022009192A
Other languages
English (en)
Inventor
ERIKSSON Helena
Kaye Joel
Törngren Marie
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of BR112022009192A2 publication Critical patent/BR112022009192A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPOSIÇÃO, MÉTODO PARA TRATAR UMA DOENÇA OCULAR OU DISTÚRBIO OCULAR, E, USO DE UM COMPOSTO. A presente invenção refere-se a compostos para o tratamento de uma doença ou distúrbio associado à vascularização excessiva do olho, como por exemplo, neovascularização da córnea, neovascularização da íris, neovascularização do corpo ciliar, pannus na córnea, neovascularização da coroide, neovascularização da retina, degeneração macular relacionada à idade úmida, retinopatia diabética proliferativa, retinopatia da prematuridade e retinopatia isquêmica.
BR112022009192A 2019-12-19 2020-12-18 Composição, método para tratar uma doença ocular ou distúrbio ocular, e, uso de um composto BR112022009192A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19218062 2019-12-19
EP20156158 2020-02-07
PCT/EP2020/086993 WO2021123142A1 (en) 2019-12-19 2020-12-18 Compounds for treatment of eye diseases associated with excessive vascularisation

Publications (1)

Publication Number Publication Date
BR112022009192A2 true BR112022009192A2 (pt) 2022-07-26

Family

ID=74141502

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009192A BR112022009192A2 (pt) 2019-12-19 2020-12-18 Composição, método para tratar uma doença ocular ou distúrbio ocular, e, uso de um composto

Country Status (15)

Country Link
US (2) US11478465B2 (pt)
EP (2) EP4094765A1 (pt)
JP (1) JP2023509336A (pt)
KR (1) KR20220118419A (pt)
CN (1) CN114845718A (pt)
AU (1) AU2020408179A1 (pt)
BR (1) BR112022009192A2 (pt)
CA (1) CA3157394A1 (pt)
DK (1) DK3886858T3 (pt)
ES (1) ES2921360T3 (pt)
IL (1) IL293469B2 (pt)
MX (1) MX2022006439A (pt)
PL (1) PL3886858T3 (pt)
WO (1) WO2021123142A1 (pt)
ZA (1) ZA202204939B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020408179A1 (en) * 2019-12-19 2022-06-30 Active Biotech Ab Compounds for treatment of eye diseases associated with excessive vascularisation
WO2022207773A1 (en) 2021-04-01 2022-10-06 Active Biotech Ab Laquinimod formulation for ocular use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
EP2376456A2 (en) 2008-12-17 2011-10-19 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
CN102984939A (zh) * 2010-07-09 2013-03-20 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
EA201490377A1 (ru) 2011-07-28 2014-11-28 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
CN104884049A (zh) * 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
WO2015060812A1 (en) 2013-10-21 2015-04-30 Howard University Treating ocular disease with efflux transporter inhibitors
US20160310417A1 (en) * 2013-12-20 2016-10-27 Emory University Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
WO2017120355A1 (en) 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
EP3654941A1 (en) * 2017-07-17 2020-05-27 Keith Roizman Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases
US10759807B2 (en) 2017-12-22 2020-09-01 Chemocentryx, Inc. Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
AU2018388655C1 (en) 2017-12-22 2023-03-23 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
US11608336B2 (en) 2018-04-02 2023-03-21 Chemocentryx, Inc. Prodrugs of fused-bicyclic C5aR antagonists
AU2020408179A1 (en) * 2019-12-19 2022-06-30 Active Biotech Ab Compounds for treatment of eye diseases associated with excessive vascularisation

Also Published As

Publication number Publication date
ZA202204939B (en) 2023-12-20
IL293469A (en) 2022-08-01
US11478465B2 (en) 2022-10-25
CA3157394A1 (en) 2021-06-24
EP3886858B1 (en) 2022-05-11
IL293469B2 (en) 2024-04-01
MX2022006439A (es) 2022-07-19
US20210322400A1 (en) 2021-10-21
IL293469B1 (en) 2023-12-01
EP4094765A1 (en) 2022-11-30
KR20220118419A (ko) 2022-08-25
JP2023509336A (ja) 2023-03-08
EP3886858A1 (en) 2021-10-06
CN114845718A (zh) 2022-08-02
PL3886858T3 (pl) 2022-08-29
ES2921360T3 (es) 2022-08-24
DK3886858T3 (da) 2022-08-22
US20230066364A1 (en) 2023-03-02
AU2020408179A1 (en) 2022-06-30
WO2021123142A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
BR112022009192A2 (pt) Composição, método para tratar uma doença ocular ou distúrbio ocular, e, uso de um composto
AR052172A1 (es) Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares
MX347226B (es) Tratamiento de enfermedad ocular.
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
MX2020001644A (es) Tratamiento de afecciones oftalmicas tales como degeneracion macular, glaucoma y retinopatia diabetica usando agentes farmaceuticos que eliminan celulas senescentes.
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
CL2023001596A1 (es) Composiciones y métodos para el tratamiento de enfermedades oculares
Hatz et al. Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized study
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
BR112023023002A2 (pt) Regimes estendidos de antagonistas de vegf em altas doses para tratamento de doenças oculares angiogênicas
TN2016000259A1 (en) Salbutamol (albuterol) eye protective medicament.
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
RU2010135224A (ru) Способ хирургического лечения макулярного отека после факоэмульсификации катаракты
BR0307013A (pt) Usos farmacêuticos
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
Manayath et al. Low-fluence photodynamic therapy for early onset choroidal neovascular membrane following laser in situ keratomileusis
Kokorev The analysis of risk factors of development of macular edema after phacoemulsification
MX2023012826A (es) Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina.
Soheilian et al. Surgery for optic neuropathy
BR112023022474A2 (pt) Composições de fator de crescimento para o tratamento de doença ocular
BR112023022561A2 (pt) Métodos e composições para o tratamento de retinopatia diabética e condições relacionadas
Ning et al. Effect of vitrectomy timing on long-term efficacy in patients with vitreous hemorrhage due to proliferative diabetic retinopathy
Karliychuk EFFICACY OF NEUROPROTECTIVE SUPPORT OF THE PATIENTS WITH DIABETES MELLITUS DURING PANRETINAL LASER PHOTOCOAGULATION
BR112023025827A2 (pt) Composto antagonista de canal trpa1 para uso em doenças degenerativas da retina